Fiocruz and Servier join forces for medicines against chronic diseases
Through the Institute of Drug Technology (Farmanguinhos) and independent French laboratory Servier, Fiocruz has signed a Memorandum of Understanding for technical cooperation to develop new drugs against chronic diseases, from a new pharmaceutical platform.
This is an innovative technology based on the prolonged release of the active ingredient in the body, resulting in efficacy, safety, and more compliance and practicality for patients.
Initially, the partnership involves the development of drugs to treat cardiovascular diseases, such as angina, ischemia, and hypertension. In the second phase, with acquired expertise, the new platform will also be able to be used to develop new treatment options for neglected diseases, such as malaria, tuberculosis, and AIDS, for instance.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze